435 related articles for article (PubMed ID: 1892184)
21. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
Weber-Diehl F; Lehnert J; Lachnit U
Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
[TBL] [Abstract][Full Text] [Related]
22. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
23. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
24. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
25. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
26. Changes in androgens during treatment with four low-dose contraceptives.
Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
[TBL] [Abstract][Full Text] [Related]
27. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
28. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
Kuhl H; Gahn G; Romberg G; März W; Taubert HD
Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
[TBL] [Abstract][Full Text] [Related]
29. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
30. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
31. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
Sinofsky FE; Pasquale SA
Am J Obstet Gynecol; 1998 Feb; 178(2):300-4. PubMed ID: 9500490
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
33. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
Fruzzetti F; Ricci C; Fioretti P
Contraception; 1994 Jun; 49(6):579-92. PubMed ID: 8070263
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
35. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
Sobbrio GA; Granata A; Granese D; D'Arrigo F; Panacea A; Nicita R; Pullè C; Trimarchi F
Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle.
Kuhnz W; Gansau C; Fuhrmeister A
Contraception; 1992 Jul; 46(1):29-40. PubMed ID: 1424621
[TBL] [Abstract][Full Text] [Related]
37. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
Hümpel M; Täuber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B; Seifert W; Schütt B
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
[TBL] [Abstract][Full Text] [Related]
38. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
[TBL] [Abstract][Full Text] [Related]
39. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
40. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
